Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Visa Inc (V) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Visa Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Visa Inc trades at $349.76 (market cap $663.65B). The key difference: Visa Inc is far larger — about 16.6× Alnylam Pharmaceuticals, Inc.'s market cap, and Visa Inc pays a 0.77% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | V | |
|---|---|---|
Market Cap | $39.89B | $663.65B |
Sector | Health | Financials |
52-Week High | $491.22 | $362.13 |
52-Week Low | $278.09 | $295.52 |
Enterprise Value | $38.15B | $674.24B |
Volume | — | 10,431,336 |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Visa (V) trades at $348.97, up 0.22% with strong technical momentum above key support at $345. The company demonstrates robust fundamentals with 2025 revenue of $40B and net income margin of 51.68%, though valuation multiples remain elevated at P/E 30.42. Recent earnings beats and a bullish analyst consensus with 85% buy ratings support the positive outlook, while the company advances AI-driven commerce initiatives through new partnerships.
Visa presents a compelling long-term investment case with consistent earnings growth and dominant market position, though premium valuation and emerging payment technology competition pose risks. Wall Street's $395 consensus target implies 13% upside potential, supported by strong cash flow generation and strategic positioning in digital payments evolution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
